Time to first clinical benefit in heart failure with preserved ejection fraction: a study-level meta-analysis of randomized controlled trials with reconstructed time-to-event data

Back

HFA Premium Access

Time to first clinical benefit in heart failure with preserved ejection fraction: a study-level meta-analysis of randomized controlled trials with reconstructed time-to-event data

Session: Tailoring heart failure therapies on patient profiles

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Doctor C. Basile (Naples, IT)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Christian Basile

University of Naples Federico II, Naples (Italy)

1 presentation

1 follower

6 more presentations in this session

A novel ERBB4 agonist attenuates cardiac remodelling after myocardial infarction in a sex-specific manner

Speaker: Miss B. Goovaerts (Antwerp, BE)

Effect of intravenous ferric derisomaltose on outcomes in heart failure with or without ischaemic heart disease in the IRONMAN trial.

Speaker: Professor J. Cleland (Glasgow, GB)

Sex differences in the prognostic role of achieving target doses of heart failure with reduced ejection fraction medications: data from the Swedish Heart Failure Registry

Speaker: Doctor D. Stolfo (Trieste, IT)

Phenotyping of patients with chronic obstructive pulmonary disease and heart failure: data from the swedish heart failure registry

Speaker: Assistant Professor P. Becher (Hamburg, DE)

Sotagliflozin is effective in reducing heart failure risk of events in patients with HFpEF

Speaker: Doctor M. Davies (The Woodlands, US)

Access the full session

Tailoring heart failure therapies on patient profiles

Speakers: Doctor C. Basile, Miss B. Goovaerts, Professor J. Cleland, Doctor D. Stolfo, Assistant Professor P. Becher...

Access

Video

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources